Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AT-7687
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Antag Receives FDA Clearance For IND Application For AT-7687
Details : AT-7687 is a peptide GIP receptor antagonist designed for once-weekly subcutaneous, currently, it is being evaluated in the treatment of obesity.
Product Name : AT-7687
Product Type : Peptide
Upfront Cash : Inapplicable
September 10, 2024
Lead Product(s) : AT-7687
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AT-7687
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Versant Ventures
Deal Size : $84.0 million
Deal Type : Series A Financing
Antag Therapeutics Announces €80 Million Series A Financing
Details : The proceeds from the financing will be used for the development of Antag's lead molecule AT-7687. It is a peptide designed to be co-administrated with current or future obesity therapies.
Product Name : AT-7687
Product Type : Peptide
Upfront Cash : Undisclosed
April 12, 2024
Lead Product(s) : AT-7687
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Versant Ventures
Deal Size : $84.0 million
Deal Type : Series A Financing
Reset All
